Symbols / CLRB Stock $3.05 -0.33% Cellectar Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
CLRB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. James V. Caruso
Exch · Country NCM · United States
Market Cap 24.32M
Enterprise Value 2.09M
Income -21.79M
Sales —
FCF (ttm) -16.43M
Book/sh 1.89
Cash/sh 3.11
Employees 11
Insider 10d —
IPO Nov 10, 2005
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.16
PEG —
P/S —
P/B 1.61
P/C —
EV/EBITDA -0.09
EV/Sales —
Quick Ratio 2.78
Current Ratio 2.96
Debt/Eq 4.13
LT Debt/Eq —
EPS (ttm) -8.35
EPS next Y -1.42
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-04
ROA -71.01%
ROE -170.27%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 7.98M
Shs Float 4.08M
Insider Own 2.08%
Instit Own 4.76%
Short Float 0.55%
Short Ratio 0.80
Short Interest 22.95K
52W High 20.70
vs 52W High -85.27%
52W Low 2.43
vs 52W Low 25.51%
Beta 0.43
Impl. Vol. —
Rel Volume 0.19
Avg Volume 1.00M
Volume 194.24K
Target (mean) $10.50
Tgt Median $10.50
Tgt Low $10.00
Tgt High $11.00
# Analysts 2
Recom Strong_buy
Prev Close $3.06
Price $3.05
Change -0.33%
About

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.50
Mean price target
2. Current target
$3.05
Latest analyst target
3. DCF / Fair value
$-37.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.05
Low
$10.00
High
$11.00
Mean
$10.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-10 up Maxim Group Hold → Buy $10
2025-05-14 down Maxim Group Buy → Hold —
2024-12-11 down Oppenheimer Outperform → Perform —
2024-11-19 main Oppenheimer Outperform → Outperform $12
2024-03-28 main Roth MKM Buy → Buy $28
2024-03-28 reit Oppenheimer Outperform → Outperform $12
2024-03-04 reit Roth MKM Buy → Buy $20
2022-11-04 main HC Wainwright & Co. — → Buy $4
News
RSS: Latest CLRB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-12 NEIS JOHN P Director — 198 $3.70 $732
2025-07-02 CARUSO JAMES V Chief Executive Officer — 10,000 $4.99 $49,900
2025-07-02 KOLEAN CHAD J Chief Financial Officer — 5,000 $4.99 $24,950
2025-07-02 LONGCOR JARROD Chief Operating Officer — 10,000 $4.99 $49,900
2025-01-10 LONGCOR JARROD Chief Operating Officer — 30,000 $0.28 $8,400
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
22.98
-55.62%
51.78
+32.90%
38.96
+35.22%
28.81
Research And Development
11.50
-56.00%
26.14
-4.14%
27.27
+49.28%
18.27
Selling General And Administration
11.48
-55.22%
25.64
+119.26%
11.69
+10.87%
10.55
General And Administrative Expense
11.48
-55.22%
25.64
+119.26%
11.69
+10.87%
10.55
Other Gand A
11.48
-55.22%
25.64
+119.26%
11.69
+10.87%
10.55
Total Expenses
22.98
-55.62%
51.78
+32.90%
38.96
+35.22%
28.81
Operating Income
-22.98
+55.62%
-51.78
-32.90%
-38.96
-35.22%
-28.81
Total Operating Income As Reported
-22.98
+55.62%
-51.78
-32.90%
-38.96
-35.22%
-28.81
EBITDA
-22.77
+55.78%
-51.49
-32.80%
-38.77
-35.24%
-28.67
Normalized EBITDA
-23.52
+63.97%
-65.28
-86.62%
-34.98
-8.31%
-32.30
Reconciled Depreciation
0.21
-26.76%
0.29
+51.61%
0.19
+29.60%
0.15
EBIT
-22.98
+55.62%
-51.78
-32.90%
-38.96
-35.22%
-28.81
Total Unusual Items
0.75
-94.54%
13.79
+464.25%
-3.79
-204.24%
3.63
Total Unusual Items Excluding Goodwill
0.75
-94.54%
13.79
+464.25%
-3.79
-204.24%
3.63
Special Income Charges
—
—
—
—
Net Income
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Pretax Income
-21.79
+51.05%
-44.52
-3.93%
-42.83
-34.46%
-31.85
Net Non Operating Interest Income Expense
0.44
-64.07%
1.21
+212.76%
0.39
+153.84%
0.15
Net Interest Income
0.44
-64.07%
1.21
+212.76%
0.39
+153.84%
0.15
Interest Income Non Operating
0.44
-64.07%
1.21
+212.76%
0.39
+153.84%
0.15
Interest Income
0.44
-64.07%
1.21
+212.76%
0.39
+153.84%
0.15
Other Income Expense
0.75
-87.54%
6.05
+242.15%
-4.26
-33.39%
-3.19
Other Non Operating Income Expenses
—
-7.74
-1547.51%
-0.47
+93.11%
-6.82
Gain On Sale Of Security
0.75
-94.54%
13.79
+464.25%
-3.79
-204.24%
3.63
Tax Provision
0.00
-100.00%
0.07
+210.00%
-0.06
+0.00%
-0.06
Tax Rate For Calcs
0.00
-100.00%
0.00
+14900.00%
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
2.90
+54737.98%
-0.01
-181.07%
0.01
Net Income Including Noncontrolling Interests
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Net Income From Continuing Operation Net Minority Interest
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Net Income From Continuing And Discontinued Operation
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Net Income Continuous Operations
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Normalized Income
-22.54
+59.36%
-55.48
-42.30%
-38.99
-10.08%
-35.42
Net Income Common Stockholders
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Diluted EPS
—
-41.89
+60.10%
-105.00
+13.58%
-121.50
Basic EPS
—
-36.52
+65.22%
-105.00
+13.58%
-121.50
Basic Average Shares
—
1.22
+199.65%
0.41
+73.22%
0.24
Diluted Average Shares
—
1.24
+203.92%
0.41
+73.22%
0.24
Diluted NI Availto Com Stockholders
-21.79
+51.12%
-44.58
-4.23%
-42.77
-34.53%
-31.79
Line Item Trend 2022-12-31
Total Assets
21.59
Current Assets
20.53
Cash Cash Equivalents And Short Term Investments
19.87
Cash And Cash Equivalents
19.87
Prepaid Assets
—
Other Current Assets
0.66
Total Non Current Assets
1.06
Net PPE
0.98
Gross PPE
1.67
Accumulated Depreciation
-0.69
Properties
0.00
Buildings And Improvements
0.56
Machinery Furniture Equipment
0.80
Other Properties
0.56
Leases
0.31
Other Non Current Assets
0.08
Total Liabilities Net Minority Interest
13.44
Current Liabilities
11.50
Payables And Accrued Expenses
4.56
Payables
2.56
Accounts Payable
2.56
Current Accrued Expenses
2.00
Pensionand Other Post Retirement Benefit Plans Current
0.92
Current Debt And Capital Lease Obligation
0.05
Current Capital Lease Obligation
0.05
Other Current Liabilities
5.97
Total Non Current Liabilities Net Minority Interest
1.94
Long Term Debt And Capital Lease Obligation
0.55
Long Term Capital Lease Obligation
0.55
Preferred Securities Outside Stock Equity
1.38
Stockholders Equity
8.15
Common Stock Equity
8.15
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.31
Ordinary Shares Number
0.31
Additional Paid In Capital
168.14
Retained Earnings
-159.99
Total Equity Gross Minority Interest
8.15
Total Capitalization
8.15
Working Capital
9.03
Invested Capital
8.15
Total Debt
0.60
Capital Lease Obligations
0.60
Net Tangible Assets
8.15
Tangible Book Value
8.15
Preferred Shares Number
0.00
Preferred Stock Equity
1.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.12
+51.41%
-47.58
-46.97%
-32.38
-28.37%
-25.22
Cash Flow From Continuing Operating Activities
-23.12
+51.41%
-47.58
-46.97%
-32.38
-28.37%
-25.22
Net Income From Continuing Operations
-21.79
+51.12%
-44.58
-4.23%
-42.77
-49.54%
-28.60
Depreciation Amortization Depletion
0.21
-26.76%
0.29
+51.61%
0.19
+29.60%
0.15
Depreciation And Amortization
0.21
-26.76%
0.29
+51.61%
0.19
+29.60%
0.15
Other Non Cash Items
0.08
+16.50%
0.07
+12.68%
0.06
-35.81%
0.09
Stock Based Compensation
2.26
-47.02%
4.27
+77.27%
2.41
+65.89%
1.45
Operating Gains Losses
-0.75
+87.24%
-5.91
-238.72%
4.26
+125626.93%
0.00
Gain Loss On Investment Securities
-0.75
+87.54%
-6.05
-242.15%
4.26
—
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.00
Change In Working Capital
-3.13
-81.20%
-1.73
-149.65%
3.48
+106.43%
1.68
Change In Prepaid Assets
0.12
+262.35%
-0.07
+57.68%
-0.17
-184.97%
0.20
Change In Payables And Accrued Expense
-3.16
-98.44%
-1.59
-143.06%
3.70
+127.91%
1.62
Change In Other Current Liabilities
-0.08
-43.13%
-0.06
-16.00%
-0.05
+64.70%
-0.14
Investing Cash Flow
-0.01
+94.36%
-0.10
+87.94%
-0.86
-282.37%
-0.23
Cash Flow From Continuing Investing Activities
-0.01
+94.36%
-0.10
+87.94%
-0.86
-282.37%
-0.23
Net PPE Purchase And Sale
-0.01
+94.36%
-0.10
+87.94%
-0.86
-282.37%
-0.23
Purchase Of PPE
-0.01
+94.36%
-0.10
+87.94%
-0.86
-282.37%
-0.23
Capital Expenditure
-0.01
+94.36%
-0.10
+87.94%
-0.86
-282.37%
-0.23
Financing Cash Flow
13.03
-78.78%
61.41
+167.71%
22.94
+138.69%
9.61
Cash Flow From Continuing Financing Activities
13.03
-78.78%
61.41
+167.71%
22.94
+138.69%
9.61
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
5.79
0.00
—
9.61
Proceeds From Stock Option Exercised
7.24
-88.21%
61.41
+7677.05%
0.79
0.00
Changes In Cash
-10.09
-173.54%
13.72
+233.22%
-10.30
+34.96%
-15.84
Beginning Cash Position
23.29
+143.48%
9.56
-51.85%
19.87
-44.36%
35.70
End Cash Position
13.20
-43.34%
23.29
+143.48%
9.56
-51.85%
19.87
Free Cash Flow
-23.12
+51.51%
-47.69
-43.46%
-33.24
-30.62%
-25.45
Interest Paid Supplemental Data
—
—
—
—
Common Stock Issuance
5.79
0.00
—
9.61
Issuance Of Capital Stock
5.79
0.00
-100.00%
22.15
+130.47%
9.61
Net Preferred Stock Issuance
—
0.00
-100.00%
22.15
+130.47%
9.61
Preferred Stock Issuance
—
0.00
-100.00%
22.15
+130.47%
9.61
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category